|
Market Closed -
Nasdaq
20:00:00 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1.470 USD | +4.26% |
|
+8.09% | +12.21% |
| 10-12 | MediciNova Phase 2 Trial in Fatty Liver Disease Drug Misses Primary Endpoints | MT |
| 10-12 | Medicinova, Inc. Provides Update on Mn-001 Phase 2 Clinical Trial Results and Mn-166 Combat-Als Trial | CI |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MNOV | Delayed | |
Japan Exchange
| 4875 | Delayed | |
|
CBOE
| MNOV | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 2.16 | 3.45 | 3.32 |
| Spread/Res. | -31.94% | -57.39% | -55.72% |
| Spread/Supp. | +19.51% | +19.51% | +19.51% |
| Support | 1.23 | 1.23 | 1.23 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- MNOV Stock
- Charts MediciNova, Inc.
Select your edition
All financial news and data tailored to specific country editions
